Maravai Lifesciences price target lowered to $9 from $10 at Baird
The Fly

Maravai Lifesciences price target lowered to $9 from $10 at Baird

Baird analyst Catherine Schulte lowered the firm’s price target on Maravai Lifesciences (MRVI) to $9 from $10 and keeps an Outperform rating on the shares. The firm said they reported 3Q results below expectations, with both segments light versus the firm’s model. In NAP, the company noted soft research/discovery demand, a lack of larger drop-in orders, and a few GMP program timing delays into 2025.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App